A Phase 1 interventional study of ASP2020 in Stargardt Disease, Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy, sponsored by Astellas Institute for Regenerative Medicine. Recruiting at 4 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Astellas Institute for Regenerative Medicine (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.
Among the 42 studies in Stargardt Disease with a site in United States, this one is the 14th largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 17 of the 24 other live ones, and was the 42nd registered.
67 studies on the registry are indexed under Stargardt Disease; 26 are open to participants now.
Browse Stargardt Disease studies →16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:
Alkeus Pharmaceuticals, Inc. · Sites in United States
Ages 8–45
Cellio Therapeutics Inc · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 6+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Stargardt Disease studies recruiting now, 14 (61%) set no upper age limit and 7 (30%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 16 · Phase 3 5
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is close to the median of 30 across 43 interventional studies indexed under Stargardt Disease.
Median enrollment 41 across the 26 interventional studies, 63 across the 16 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Institute for Regenerative Medicine, one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Institute for Regenerative Medicine is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Astellas Pharma Inc has 7 studies filed under Stargardt Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Stargardt Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06435000Splice BioAn Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene | 2026-12 |
| NCT07502664Ray Therapeutics, Inc.Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) | 2027-02 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
| NCT06591806AAVantgarde Bio SrlAn Observational Study in Children and Adults With Stargardt Disease | 2027-06-30 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Stargardt Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to loss of central vision, which can make it harder to read, recognize faces or see fine details. What's seen out of the corner of the eye (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically begins in childhood or teenage years but may also develop in adulthood. As well as STGD, there are other macular dystrophies that look very similar to STGD and are called STGD-like macular dystrophies. These are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies.
This is an early development study of ASP2020 in adults, teenagers, and children with STGD-type macular dystrophies. ASP2020 are human stem cells which have been changed into cells found in the macula. In this study ASP2020 will be given to people for the first time. The main aim of the study is to check the safety of ASP2020 and how well people tolerate it. Other aims are to learn if people have an immune reaction to ASP2020, and if there are signs that the stem cells replace damaged cells in the retina, and vision improves for people with STGD-type macular dystrophies.
ASP2020 will be given as a single injection into the eye, under the retina. This requires a surgical procedure where the person is put to sleep by a general anesthetic. At the end of surgery, a steroid will be injected into the eye to reduce any swelling.
The study has 2 parts. In Part 1, different small groups will receive a lower to higher dose of ASP2020. This is done to find a suitable dose to use in Part 2. The adults will receive the lower dose and higher dose before the teenagers. There will be a 6-month gap between the last adult receiving the lower dose of ASP2020 and the first teenager receiving the same lower dose. This will also happen for the last adult receiving the higher dose of ASP2020 and the first teenager receiving the higher dose of ASP2020. Any medical problems will be recorded for each dose in each group. Children will not receive ASP2020 in Part 1.
In Part 2, different groups of adults, teenagers and children will receive the most suitable dose of ASP2020 worked out from Part 1.
People will be in the study for about 1 year and they will visit the clinic several times. In both parts of the study, safety checks will be done at each visit, and the study doctors will continue to check for any medical problems throughout the study. Various eye tests and eye imaging will be done throughout the study. Blood tests will also be done at some of the visits during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented clinical diagnosis of macular dystrophy with a STGD-type clinical presentation and molecular confirmation, defined as either:
BCVA ranging from 20/500 to 20/40 (equivalent to 15 to 70 ETDRS letters)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult participants will receive a single low dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Drug: ASP2020
Adult participants will receive a single high dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Drug: ASP2020
Adolescent participants will receive single low dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Drug: ASP2020
Adolescent participants will receive single high dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Drug: ASP2020
Adult participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Drug: ASP2020
Pediatric participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Drug: ASP2020
Subretinal Injection
Number of participants with treatment-emergent adverse events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs are defined as an AE observed after administration of ASP2020 or pre-existing AE that worsen in severity or frequency following administration of ASP2020.
Time frame: Up to 52 weeks
Number of participants with serious adverse events (SAEs)
An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important events.
Time frame: Up to 52 weeks
Number of participants with adverse events of special interest (AESIs)
AESIs include, but are not limited to, the following: * Ectopic, excessive, or aberrant cell growth of ASP2020, including proliferative changes * Immune-mediated reactions, including unexpected or clinically significant inflammatory responses * Any new diagnosis of malignancy * Any clinically significant AEs possibly or definitely related to ASP2020 * Clinically significant AEs related to the surgical administration procedure
Time frame: Up to 52 weeks
Number of participants with greater than or equal to 15 letter loss in best corrected visual acuity (BCVA) from baseline
BCVA will be measured from the Early Treatment of Diabetic Retinopathy Study (ETDRS) letters chart.
Time frame: Up to 52 weeks
Number of participants with significant changes in vital signs from baseline
Number of participants with significant changes in vital signs from baseline will be reported.
Time frame: Up to 52 weeks
Number of participants with significant changes in laboratory values from baseline
Number of participants with significant changes in laboratory values from baseline will be reported.
Time frame: Up to 52 weeks
Change from baseline in BCVA
BCVA will be measured from the ETDRS letters chart.
Time frame: Baseline and week 26, 52 or Early Termination (ET) visit whichever occurs first
Change from baseline in low luminance visual acuity (LLVA)
LLVA will be measured from the ETDRS letters chart.
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in Minnesota Reading Acuity Chart (MNREAD) parameters
MNREAD evaluates near reading acuity, reading speed and critical print size.
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in mesopic macular sensitivity
Mean sensitivity, point-wise sensitivity (PWS), scotomatous/non-seen point count) will be measured by mesopic microperimetry.
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in central retinal thickness (CRT)
CRT will be measured by spectral- domain optical coherence tomography (SD-OCT).
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in total photoreceptor thickness (TPT)
TPT will be measured by SD-OCT.
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in ellipsoid zone (EZ) integrity
EZ integrity will be measured by SD- OCT.
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in outer nuclear layer (ONL)
ONL will be measured by SD-OCT.
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in retinal pigment epithelium (RPE) integrity
RPE structural integrity will be measured by SD-OCT.
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in questionably decreased autofluorescence (QDAF)
QDAF will be measured with fundus autofluorescence (FAF).
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in definitely decreased autofluorescence (DDAF)
DDAF will be measured with FAF.
Time frame: Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in anti-human leukocyte antigen (HLA) antibodies
Anti-HLA antibodies will be measured from the serum samples.
Time frame: Baseline and week 4, 12 and 52 or ET visit whichever occurs first
Change from baseline in anti herpes simplex virus thymidine kinase (HSV- TK) antibodies
Anti HSV-TK antibodies will be measured from the serum samples.
Time frame: Baseline and week 4, 12 and 52 or ET visit whichever occurs first
Change from baseline in cytokines
Cytokines will be measured from the serum samples.
Time frame: Baseline and week 1, 4, 12 and 52 or ET visit whichever occurs first
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astellas Institute for Regenerative Medicine →